Holen Sie sich die Stockscreener-App
92.38
0.50%
0.46
Handel nachbörslich:
91.00
-1.38
-1.49%
Schlusskurs vom Vortag:
$91.92
Offen:
$92.58
24-Stunden-Volumen:
1.00M
Relative Volume:
0.44
Marktkapitalisierung:
$18.24B
Einnahmen:
$7.68B
Nettoeinkommen (Verlust:
$903.80M
KGV:
20.76
EPS:
4.45
Netto-Cashflow:
$1.14B
1W Leistung:
+0.23%
1M Leistung:
+0.12%
6M Leistung:
-14.49%
1J Leistung:
-18.51%
1-Tages-Spanne:
$91.97
$92.98
1-Wochen-Bereich:
$89.24
$92.98
52-Wochen-Spanne:
$89.24
$116.71
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Firmenname
Zimmer Biomet Holdings Inc
Sektor
Branche
Telefon
(574) 267-6131
Adresse
345 EAST MAIN STREET, WARSAW, IN
Vergleichen Sie ZBH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
92.38 | 18.24B | 7.68B | 903.80M | 1.14B | 4.45 |
|
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-10 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-21 | Hochstufung | Argus | Hold → Buy |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-10-20 | Eingeleitet | ROTH MKM | Neutral |
| 2023-08-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-05-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-03-29 | Eingeleitet | UBS | Sell |
| 2023-03-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-01-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Underweight |
| 2022-10-12 | Eingeleitet | Jefferies | Underperform |
| 2022-05-27 | Herabstufung | Needham | Buy → Hold |
| 2022-04-13 | Herabstufung | Truist | Buy → Hold |
| 2022-04-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Underperform |
| 2022-03-02 | Herabstufung | Loop Capital | Buy → Hold |
| 2022-02-08 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-08 | Bestätigt | Citigroup | Buy |
| 2022-02-08 | Bestätigt | Deutsche Bank | Hold |
| 2022-02-08 | Bestätigt | JMP Securities | Mkt Outperform |
| 2022-02-08 | Bestätigt | JP Morgan | Neutral |
| 2022-02-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-08 | Bestätigt | Stifel | Buy |
| 2022-02-08 | Bestätigt | Truist | Buy |
| 2022-02-08 | Bestätigt | UBS | Neutral |
| 2022-02-08 | Bestätigt | Wells Fargo | Underweight |
| 2022-02-02 | Herabstufung | UBS | Buy → Neutral |
| 2022-01-19 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-12-09 | Herabstufung | Needham | Strong Buy → Buy |
| 2021-12-07 | Eingeleitet | Loop Capital | Buy |
| 2021-11-23 | Herabstufung | Argus | Buy → Hold |
| 2021-09-14 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-09 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-18 | Bestätigt | Needham | Strong Buy |
| 2020-10-20 | Eingeleitet | Northland Capital | Market Perform |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-08-05 | Bestätigt | Needham | Strong Buy |
| 2020-04-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-04-07 | Bestätigt | Needham | Strong Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-07 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2020-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2019-12-04 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-10-07 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-09-18 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-08-12 | Hochstufung | Argus | Hold → Buy |
| 2019-07-30 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-06-11 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2019-04-24 | Hochstufung | Needham | Buy → Strong Buy |
Alle ansehen
Zimmer Biomet Holdings Inc Aktie (ZBH) Neueste Nachrichten
Zimmer Biomet sued for violating Treace Medical patents related to bunion treatment - MSN
Highridge sells bone healing business to Avista - BioWorld MedTech
Treace Medical Concepts (TMCI) Sues Zimmer Biomet Over Patent Infringements - GuruFocus
Zimmer Biomet Facing Patent Infringement Lawsuit From Treace Medical - marketscreener.com
Treace Medical sues Zimmer Biomet over patent infringement - Investing.com Australia
Treace Medical sues Zimmer Biomet over patent infringement By Investing.com - Investing.com Nigeria
Zimmer Biomet faces patent suit from Treace Medical (TMCI) - Seeking Alpha
Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology - The Manila Times
Treace Medical files patent infringement suit against Zimmer Biomet - TipRanks
Treace Medical Concepts Files Patent Infringement Suit Against Zimmer Biomet - marketscreener.com
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Zimmer Biomet Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 31, 2017ZBH - ACCESS Newswire
zimmer biomet shareholders approve stock incentive plan amendments By Investing.com - Investing.com South Africa
Rep. Robert Bresnahan, Jr. Sells Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares - Defense World
zimmer biomet shareholders approve stock incentive plan amendments - Investing.com
Zimmer Biomet Approves Amendments at Annual Meeting - TipRanks
Zimmer Biomet Holdings (NYSE:ZBH) Has Affirmed Its Dividend Of $0.24 - Yahoo Finance
Zimmer Biomet Holdings' (NYSE:ZBH) Dividend Will Be $0.24 - simplywall.st
Zimmer Biomet sets quarterly dividend at $0.24 per share By Investing.com - Investing.com South Africa
Zimmer Biomet Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Knee Replacement Market Detailed in New Research ReportZimmer Biomet, Stryker - openPR.com
Zimmer Biomet Keeps Quarterly Dividend at $0.24 a Share, Payable Around July 31 to Shareholders of Record on June 26 - marketscreener.com
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025 - GuruFocus
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025 | ZBH Stock News - GuruFocus
Zimmer Biomet sets quarterly dividend at $0.24 per share - Investing.com
Zacks Research Forecasts Weaker Earnings for Zimmer Biomet - Defense World
Zimmer Biomet Chairman, President and CEO Ivan Tornos Joins OREF Board of Trustees - Yahoo Finance
A Look Back at Surgical Equipment & ConsumablesDiversified Stocks’ Q1 Earnings: Zimmer Biomet (NYSE:ZBH) Vs The Rest Of The Pack - Yahoo Finance
Zacks Research Forecasts Reduced Earnings for Zimmer Biomet - Defense World
Zimmer Biomet names Kevin Thornal as group president, global biz - Medical Buyer
Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas - The Malaysian Reserve
Zimmer Biomet Holdings (ZBH) Appoints Kevin Thornal as Group Pre - GuruFocus
Orthopedic Oncology Market is Booming WorldwideStryker, Zimmer Biomet - openPR.com
Zimmer hires former Nevro CEO Kevin Thornal - Yahoo Finance
Zimmer Biomet Holdings (ZBH) Appoints Kevin Thornal as Group President - GuruFocus
Zimmer Biomet names new Group President for Americas By Investing.com - Investing.com South Africa
Former Nevro CEO joins Zimmer Biomet as group president - MassDevice
Hip Replacement Market is Booming WorldwideZimmer Biomet, Stryker - openPR.com
Zimmer Biomet Appoints Kevin Thornal As Group President, Global Businesses And The Americas - marketscreener.com
Zimmer Biomet Appoints Kevin Thornal as Group President - TipRanks
Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas | ZBH Stock News - GuruFocus
Zimmer Biomet names new Group President for Americas - Investing.com
Saudi Arabia Dental Implants Market Trends and Forecasts 2020-2024 & 2025-2030, Competitive Analysis of Masar Medical, Keydent, Zimmer Biomet, Dentsply Sirona, and Henry Schein - Yahoo
Zimmer Biomet Holdings (ZBH) Stock Analysis: Navigating a Potential 17.25% Upside in the Healthcare Sector - DirectorsTalk Interviews
Zimmer Biomet’s SWOT analysis: orthopedic giant’s stock navigates challenges By Investing.com - Investing.com Nigeria
Zimmer Biomet’s SWOT analysis: orthopedic giant’s stock navigates challenges - Investing.com
Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Malaysian Reserve
Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | ZBH Stock News - GuruFocus
ZBH Stock to Gain From Buyouts and Innovations Amid Macro Issues - TradingView
Zimmer Biomet Holdings, Inc. (ZBH): Among the Most Oversold Stocks to Buy According to Billionaires - Insider Monkey
Zimmer Biomet Stock Outlook: Is Wall Street Bullish or Bearish? - Nasdaq
Zimmer Biomet Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart.com
Finanzdaten der Zimmer Biomet Holdings Inc-Aktie (ZBH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.56%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):